LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer

Christopher W Murray1, Jennifer J Brady2, Mingqi Han3,4

  • 1Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA.

Nature Communications
|March 1, 2022
PubMed